Anti-fibrotic efficacy
Evaluate candidate activity in a CCl4-induced liver-fibrosis setting using protocol-defined treatment windows.
LIVER DISEASE MODEL
CCl4-Induced Liver Fibrosis Model
CCl4-induced liver fibrosis is documented within the partner model portfolio alongside TAA, HSA, liver-failure, and other hepatic injury or fibrosis study formats.
Species, induction regimen, baseline fibrosis state, treatment window, pathology, biomarkers, and exposure outputs are confirmed per program.
MODEL OVERVIEW
A documented liver-fibrosis platform for hepatic pharmacology studies.
CCl4-induced liver fibrosis can support efficacy and tissue-oriented programs, while the wider partner portfolio includes additional fibrosis and hepatic-injury models for mechanism-matched study design.
Therapeutic areaLiver fibrosis
SpeciesRat
Model formatCCl4 induced
Typical useEfficacy, Pathology, Biomarkers
TYPICAL APPLICATIONS
What this model can support.
Tissue pathology
Collect liver tissue for fibrosis-focused histology and downstream tissue analysis.
Biomarker studies
Integrate protocol-defined hepatic injury, fibrosis, or mechanism-linked biomarkers.
PK/PD integration
Link systemic or liver exposure to pharmacodynamic and efficacy readouts when required.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Liver pathology
Protocol-defined histology and fibrosis-oriented tissue assessment.
Biomarkers
Serum or tissue biomarkers relevant to liver injury, fibrosis, or the candidate mechanism.
Tissue outputs
Liver tissue collection for molecular, biochemical, or other downstream analysis.
Exposure
Plasma or liver exposure when incorporated into the study design.
Exact species and strain, induction regimen, treatment window, pathology package, endpoints, and timeline are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- CCl4 induction design
- Species, strain, and baseline disease state
- Treatment timing and duration
- Dose route and formulation
- Histology and biomarker package
- PK/PD integration requirements
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a Liver Fibrosis study.Required fields are marked with an asterisk(*).